Skip to content

Montai Therapeutics is pioneering the creation of Anthromolecule™ medicines – unlocked from a privileged class of molecules with a history of safe, human consumption — to treat and preempt chronic disease. Montai’s CONECTA™ platform comprehensively maps Anthromolecule bioactivity across pathways that drive disease. The CONECTA platform leverages rapid and ever-growing advancements in the digitization of natural chemistry and human biology coupled with powerful computational tools for linking chemical structure and bioactivity. This confluence of biotechnologies enables Montai to build a powerful, one-of-a-kind discovery platform focused on creating safe, effective, and more human-centric medicines than ever before.

Latest News from Montai Therapeutics